Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "DECITABINE FOR INJECTION" PASSES CONSISTENCY EVALUATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement

(Incorporated in the Cayman Islands with limited liability)

Website:www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"DECITABINE FOR INJECTION" PASSES CONSISTENCY EVALUATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Decitabine for injection" (product name: Qingweike (౹ၪ̙)) (specifications: 10mg, 25mg and 50mg), an anti-hematological tumor drug developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People's Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs ("Consistency Evaluation").

Decitabine is a specific inhibitor of deoxyribonucleic acid (DNA) methylation. It inhibits DNA methyltransferase through incorporation into DNA, causing DNA hypomethylation and cell differentiation or apoptosis to exert anti-tumor effects. Decitabine has shown high efficacy in the treatment of high-risk myelodysplastic syndrome (MDS), refractory and recurrent acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML).

The production and sales volume of Decitabine for injection developed by the Group has been increasing year by year since its launch in 2012. Passing the Consistency Evaluation, Decitabine for injection of the Group is recognized as an alternative to the imported pharmaceutical preparation, providing clinicians and patients with another solid choice for the treatment of MDS.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 12 March 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.